TY - GEN
T1 - Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma
T2 - Journal of Personalized Medicine
AU - Huang, Jia-Hui
AU - Chen, Shu-Huey
AU - Liao, Yu-Mei
AU - Kao, Yu-Chien
AU - Ho, Wan-Ling
AU - Chang, Hsi
AU - Tsai, Min-Lan
AU - Lee, Hsin-Lun
AU - Kuo, Chia-Chun
AU - Tseng, Sung-Hui
AU - Chang, Chia-Yau
AU - Hsieh, Kevin L.
AU - Lu, Long-Sheng
AU - Chen, Yin-Ju
AU - Chiou, Jeng-Fong
AU - Hsieh, Tsung-Han
AU - Liu, Yun-Ru
AU - Hsu, Wayne
AU - Li, Wei-Tang
AU - Wu, Yu-Chung
AU - Wu, Wei-Ciao
AU - Wang, Jinn-Li
AU - Tsai, Jia-Jia
AU - Terashima, Keita
AU - Kiyotani, Chikako
AU - Wong, Tai-Tong
AU - Miser, James S.
AU - Liu, Yen-Lin
N1 - Funding Information:
This work was supported in part by the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. The authors thank Yu-Han Chung at the Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan for her assistance with study coordination and data management.
Funding Information:
This research was funded in part by the National Science and Technology Council, Taiwan, Grant Number NSC-109-2314-B-038-072.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/4
Y1 - 2023/4
N2 - Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.
AB - Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.
KW - VDC/IE
KW - adolescent and young adult
KW - children
KW - granulocyte colony-stimulating factor
KW - interval-compressed chemotherapy
KW - round cell sarcoma
UR - http://www.scopus.com/inward/record.url?scp=85154579553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85154579553&partnerID=8YFLogxK
U2 - 10.3390/jpm13040668
DO - 10.3390/jpm13040668
M3 - Other contribution
C2 - 37109054
SN - 2075-4426
VL - 13
T3 - Journal of Personalized Medicine
ER -